Lupin Stock: Risk Return
Details
FINC137
7
2018
YES
300
Lupin Laboratories
Pharmaceuticals & Biotech
India
Corporate Finance
Abstract
On November 7, 2017, the Lupin stock hit a 52-week low of Rs.846.20 when the pharma major informed the NSE and the BSE about the warning letter it had received from the USFDA.Following the steep decline in the stock price, company's market valuation eroded by Rs 78.66 billion. Concerned over Lupin Ltd.’s margins, most of the brokerage houses cut their target price on the stock. Investors were left wondering whether they should sell the stock, hold it, or buy more. The present case uses the backdrop of Lupin stock price fluctuations to teach the concept of risk and return analysis.
Learning Objectives
The case is structured to achieve the following Learning Objectives:
- Learn the significance of risk and return analysis
- Learn how to calculate historical and expected returns on a particular stock and the market.
- Learn how to calculate historical and expected risk of a particular stock and the market.
- Learn how to measure the systematic risk (ß) of a particular stock.
- Check whether the stock is underpriced or overpriced using the CAPM model.
Keywords
Risk and return of stock; Market return and risk; Historical return and risk; Expected return and risk; Beta ;CAPM;Overpriced; Under priced
Related Case Studies
| Case Title | Details | Price | Add to Cart |
|---|---|---|---|
|
Case Title Nykaa IPO: Will It Translate the Beauty and Personal Care Market Opportunity into Big Profits?Case Code: FINC200 |
Details | 400 | Add to Cart |
|
Case Title Apple`s Green BondsCase Code: FINC199 |
Details | 300 | Add to Cart |
|
Case Title The Evergrande Crisis in ChinaCase Code: FINC197 |
Details | 500 | Add to Cart |
|
Case Title Stock Split: A Case of IRCTCCase Code: FINC189 |
Details | 400 | Add to Cart |
|
Case Title Krishna Institute of Medical Sciences IPO: Should You Invest or Not?Case Code: FINC187 |
Details | 500 | Add to Cart |